Eli Lilly issued 2023 guidance that was largely in line with our expectations, but the firm also announced the movement of two new drugs into phase 3 development based on favorable preliminary phase 2 ...
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing ...
Lilly confirmed its fourth-quarter performance and 2025 guidance released in mid-January, with 45% revenue growth and a more than doubling of non-GAAP EPS in the quarter. Management's 2025 guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback